Chlamydia Trachomatis and Neisseria Gonorrhoeae Testing from ThinPrep Vials
Chlamydia is the most frequently reported infectious disease in the United States with more than 3 million new cases estimated annually. Untreated, Chlamydia can cause pelvic inflammatory disease (PID), infertility and ectopic pregnancy. An estimated 800,000 new cases of gonorrhea are reported in the United States each year. Left untreated, gonorrhea can lead to PID and infertility.
CPA Lab offers testing for both Chlamydia Trachomatis and Neisseria Gonorrhoeae directly from the ThinPrep vial using the Gen-Probe Aptima assay. The Gen-Probe Aptima assay uses RNA amplification to increase the number of target organisms. PCR technology allows for very specific identification of both chlamydia and gonorrhea by targeting a segment of RNA unique to each organism. The amplification process takes very small quantities of genetic material and copies it until a significant detection quantity is generated. Infection may be detected before the patient is symptomatic and before progression to PID.
An aliquot of transport media is removed from the ThinPrep vial upon receipt at CPA Lab prior to Pap smear processing and sent for PCR analysis. CPA Lab is unable to add chlamydia or gonorrhea testing after the ThinPrep has been processed due to reports of less than reliable results when residual transport material is used.
Other GC/Chlamydia Collection Methods
The following collection methods also may be used in the detection of GC/chlamydia: vaginal swab specimens, urine specimens, endocervical and male urethral swab specimens.
Please contact CPA Lab for specimen collection instructions.
Turnaround time for chlamydia and neisseria testing is two days.